The U.S. Department of Human Health and Services has recommended that the DEA reclassify cannabis from Schedule I to Schedule III, meaning it would join the same category as ketamine and anabolic steroids. Rescheduling would transform the ways in which cannabinoid based research is conducted, Phie Jacobs of ScienceInsider reports. "We’re still a long way from having enough empirically sound data" says Dr. Gruber. Read the article here.
top of page
bottom of page